Needham Reiterates Hold on Inari Medical
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Hold rating on Inari Medical (NASDAQ:NARI).
July 31, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Mike Matson has reiterated a Hold rating on Inari Medical. This suggests that the analyst does not see significant upside or downside potential in the short term.
The reiteration of a Hold rating by a reputable analyst suggests that there are no major changes in the company's outlook. This typically indicates that the stock is expected to perform in line with the market or sector average.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100